MBX Biosciences (NASDAQ:MBX – Get Free Report) posted its earnings results on Thursday. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10), FiscalAI reports.
MBX Biosciences Price Performance
NASDAQ MBX traded up $0.71 during mid-day trading on Friday, reaching $67.82. 545,471 shares of the stock were exchanged, compared to its average volume of 674,146. The stock has a market cap of $3.23 billion, a P/E ratio of -28.14 and a beta of 0.10. MBX Biosciences has a one year low of $9.63 and a one year high of $72.64. The stock has a 50 day simple moving average of $52.20 and a 200-day simple moving average of $40.03.
Analysts Set New Price Targets
MBX has been the topic of a number of research reports. Citigroup restated an “outperform” rating on shares of MBX Biosciences in a research report on Tuesday, May 12th. Stifel Nicolaus set a $56.00 price target on MBX Biosciences in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a research note on Friday, July 17th. Wall Street Zen lowered shares of MBX Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Citizens Jmp increased their price objective on MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, MBX Biosciences currently has an average rating of “Moderate Buy” and an average target price of $73.38.
Institutional Investors Weigh In On MBX Biosciences
Several institutional investors and hedge funds have recently made changes to their positions in MBX. CWM LLC lifted its holdings in MBX Biosciences by 28.9% during the fourth quarter. CWM LLC now owns 1,784 shares of the company’s stock worth $56,000 after acquiring an additional 400 shares during the period. Royal Bank of Canada raised its stake in shares of MBX Biosciences by 59.6% during the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after purchasing an additional 572 shares during the period. California State Teachers Retirement System raised its stake in shares of MBX Biosciences by 64.7% during the 4th quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock worth $55,000 after purchasing an additional 689 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of MBX Biosciences in the 4th quarter worth about $28,000. Finally, Strs Ohio grew its position in MBX Biosciences by 128.6% during the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after buying an additional 900 shares during the period.
MBX Biosciences Company Profile
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.
Featured Stories
- Five stocks we like better than MBX Biosciences
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
